SEC Form 4 · accession 0001179110-17-015385
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Gesua Sive Salvadori
Officer — Executive Vice President
Period of report
Dec 14, 2017
Accepted (ET)
Dec 14, 2017 · 6:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par value | Dec 14, 2017 | M | 28,319 | $47.00 | A | 102,117 | D | |
| Common shares without par value | Dec 14, 2017 | S | 9,839 | $54.901 | D | 92,278 | D | |
| Common shares without par value | Dec 14, 2017 | S | 1,483 | $54.91 | D | 90,795 | D | |
| Common shares without par value | Dec 14, 2017 | S | 200 | $54.911 | D | 90,595 | D | |
| Common shares without par value | Dec 14, 2017 | S | 200 | $54.915 | D | 90,395 | D | |
| Common shares without par value | Dec 14, 2017 | S | 1,900 | $54.92 | D | 88,495 | D | |
| Common shares without par value | Dec 14, 2017 | S | 100 | $54.9214 | D | 88,395 | D | |
| Common shares without par value | Dec 14, 2017 | S | 6,897 | $54.93 | D | 81,498 | D | |
| Common shares without par value | Dec 14, 2017 | S | 7,700 | $54.935 | D | 73,798 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F1 | $47.00 | Dec 14, 2017 | M | 28,319 | D | Feb 20, 2017 | Feb 19, 2025 | Common shares | 28,319 | 42,479 | D |
Explanation of responses
- F1Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Remarks
These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).